Want to see AU:ATX full AI Analyst Report?
ATX Stock Chart & Stats
AU$0.14
<AU$0.01(2.33%)
At close: 4:00 PM EST
AU$0.14
<AU$0.01(2.33%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.28
Previous CloseN/A
Volume274.48K
Average Volume (3M)525.22K
Market Cap
AU$69.30M
Enterprise ValueAU$34.08M
Total Cash (Recent Filing)AU$27.85M
Total Debt (Recent Filing)AU$341.11K
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding513,312,000
10 Day Avg. Volume444,673
30 Day Avg. Volume525,217
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-12.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Equity-backed Balance SheetA large equity cushion relative to assets and low leverage materially reduces short-term solvency risk and the need for immediate high-cost financing. Over a multi-month horizon this provides runway for R&D and clinical milestones, lowering dilution risk if management paces spend to milestones.
Focused R&D PipelineA concentrated pipeline with a clear lead asset targeting focal adhesion kinase (FAK) and high‑unmet‑need indications like pancreatic cancer creates a durable strategic focus. Successful clinical progress or partnerships would meaningfully de‑risk value creation versus diversified early‑stage portfolios.
Attractive Product Economics HistoricallyHistorical high gross margins suggest the company’s products or services can scale with favorable unit economics. If clinical programs translate into commercial products, these margins could support long‑term profitability, making R&D investment potentially accretive rather than structurally loss‑making.
Bears Say
No Current RevenueThe absence of revenue undermines operational self‑funding and prevents validation of commercial demand. Over a 2–6 month horizon this remains a durable weakness: without monetized products or external financing the company must rely on capital markets or partners, raising execution and dilution risk.
Persistent Losses And Rising Cash BurnConsistent negative operating and free cash flow with accelerating burn increases the company’s need for external funding and narrows runway. This structural cash consumption pressures strategic flexibility, may force dilutive financings, and constrains the pace of clinical development over the medium term.
Negative Returns On Invested CapitalDespite a sizable equity base, persistent negative ROE indicates the company’s capital has not produced profitable operations. This long‑running inability to generate returns risks shareholder value erosion unless clinical success translates quickly to revenue or meaningful partnering occurs.
Amplia Therapeutics News
ATX FAQ
What was Amplia Therapeutics Ltd.’s price range in the past 12 months?
Amplia Therapeutics Ltd. lowest share price was AU$0.10 and its highest was AU$0.28 in the past 12 months.
What is Amplia Therapeutics Ltd.’s market cap?
Amplia Therapeutics Ltd.’s market cap is AU$69.30M.
When is Amplia Therapeutics Ltd.’s upcoming earnings report date?
Amplia Therapeutics Ltd.’s upcoming earnings report date is Nov 25, 2026 which is in 124 days.
How were Amplia Therapeutics Ltd.’s earnings last quarter?
Amplia Therapeutics Ltd. released its earnings results on May 29, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.
Is Amplia Therapeutics Ltd. overvalued?
According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Overvalued.
Does Amplia Therapeutics Ltd. pay dividends?
Amplia Therapeutics Ltd. does not currently pay dividends.
What is Amplia Therapeutics Ltd.’s EPS estimate?
Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amplia Therapeutics Ltd. have?
Amplia Therapeutics Ltd. has 513,312,000 shares outstanding.
What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?
Amplia Therapeutics Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amplia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
66.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
98.58%
Trailing 12-Months
Company Description
Amplia Therapeutics Ltd.
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Technical Analysis
Tryptamine Therapeutics
―
Neuren Pharmaceuticals Limited
―
Paradigm Biopharmaceuticals
―
Alterity Therapeutics
―
Zelira Therapeutics
―